These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

163 related articles for article (PubMed ID: 27604276)

  • 21. Synergistic Effects of Olaparib and DNA-damaging Agents in Oesophageal Squamous Cell Carcinoma Cell Lines.
    Miyamoto K; Minegaki T; Tanahashi M; Yamamoto A; Moriyama Y; Wada A; Matsumoto A; Ota K; Tanaka M; Masuda U; Tsujimoto M; Nishiguchi K
    Anticancer Res; 2019 Apr; 39(4):1813-1820. PubMed ID: 30952721
    [TBL] [Abstract][Full Text] [Related]  

  • 22. p53 Binding to the p21 promoter is dependent on the nature of DNA damage.
    Hill R; Bodzak E; Blough MD; Lee PW
    Cell Cycle; 2008 Aug; 7(16):2535-43. PubMed ID: 18719376
    [TBL] [Abstract][Full Text] [Related]  

  • 23. An evaluation in vitro of PARP-1 inhibitors, rucaparib and olaparib, as radiosensitisers for the treatment of neuroblastoma.
    Nile DL; Rae C; Hyndman IJ; Gaze MN; Mairs RJ
    BMC Cancer; 2016 Aug; 16():621. PubMed ID: 27515310
    [TBL] [Abstract][Full Text] [Related]  

  • 24. New insights into PARP inhibitors' effect on cell cycle and homology-directed DNA damage repair.
    Jelinic P; Levine DA
    Mol Cancer Ther; 2014 Jun; 13(6):1645-54. PubMed ID: 24694947
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Effects of Combined Treatment with Ionizing Radiation and the PARP Inhibitor Olaparib in BRCA Mutant and Wild Type Patient-Derived Pancreatic Cancer Xenografts.
    Lohse I; Kumareswaran R; Cao P; Pitcher B; Gallinger S; Bristow RG; Hedley DW
    PLoS One; 2016; 11(12):e0167272. PubMed ID: 28033382
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Evaluation of p21 promoter for interleukin 12 radiation induced transcriptional targeting in a mouse tumor model.
    Kamensek U; Sersa G; Cemazar M
    Mol Cancer; 2013 Nov; 12(1):136. PubMed ID: 24219565
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Radiation-induced synthetic lethality: combination of poly(ADP-ribose) polymerase and RAD51 inhibitors to sensitize cells to proton irradiation.
    Wéra AC; Lobbens A; Stoyanov M; Lucas S; Michiels C
    Cell Cycle; 2019 Aug; 18(15):1770-1783. PubMed ID: 31238782
    [TBL] [Abstract][Full Text] [Related]  

  • 28. PARP inhibitors affect growth, survival and radiation susceptibility of human alveolar and embryonal rhabdomyosarcoma cell lines.
    Camero S; Ceccarelli S; De Felice F; Marampon F; Mannarino O; Camicia L; Vescarelli E; Pontecorvi P; Pizer B; Shukla R; Schiavetti A; Mollace MG; Pizzuti A; Tombolini V; Marchese C; Megiorni F; Dominici C
    J Cancer Res Clin Oncol; 2019 Jan; 145(1):137-152. PubMed ID: 30357520
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Targeting PARP-1 with metronomic therapy modulates MDSC suppressive function and enhances anti-PD-1 immunotherapy in colon cancer.
    Ghonim MA; Ibba SV; Tarhuni AF; Errami Y; Luu HH; Dean MJ; El-Bahrawy AH; Wyczechowska D; Benslimane IA; Del Valle L; Al-Khami AA; Ochoa AC; Boulares AH
    J Immunother Cancer; 2021 Jan; 9(1):. PubMed ID: 33495297
    [TBL] [Abstract][Full Text] [Related]  

  • 30. WTp53 induction does not override MTp53 chemoresistance and radioresistance due to gain-of-function in lung cancer cells.
    Cuddihy AR; Jalali F; Coackley C; Bristow RG
    Mol Cancer Ther; 2008 Apr; 7(4):980-92. PubMed ID: 18413811
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Radiosensitization with combined use of olaparib and PI-103 in triple-negative breast cancer.
    Jang NY; Kim DH; Cho BJ; Choi EJ; Lee JS; Wu HG; Chie EK; Kim IA
    BMC Cancer; 2015 Mar; 15():89. PubMed ID: 25884663
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Histone deacetylase inhibitor, suberoylanilide hydroxamic acid (SAHA), enhances anti-tumor effects of the poly (ADP-ribose) polymerase (PARP) inhibitor olaparib in triple-negative breast cancer cells.
    Min A; Im SA; Kim DK; Song SH; Kim HJ; Lee KH; Kim TY; Han SW; Oh DY; Kim TY; O'Connor MJ; Bang YJ
    Breast Cancer Res; 2015 Mar; 17():33. PubMed ID: 25888415
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Postmitotic neurons develop a p21-dependent senescence-like phenotype driven by a DNA damage response.
    Jurk D; Wang C; Miwa S; Maddick M; Korolchuk V; Tsolou A; Gonos ES; Thrasivoulou C; Saffrey MJ; Cameron K; von Zglinicki T
    Aging Cell; 2012 Dec; 11(6):996-1004. PubMed ID: 22882466
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Small molecule inhibitors uncover synthetic genetic interactions of human flap endonuclease 1 (FEN1) with DNA damage response genes.
    Ward TA; McHugh PJ; Durant ST
    PLoS One; 2017; 12(6):e0179278. PubMed ID: 28628639
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Targeted inhibition of the ATR/CHK1 pathway overcomes resistance to olaparib and dysregulates DNA damage response protein expression in BRCA2
    Biegała Ł; Gajek A; Szymczak-Pajor I; Marczak A; Śliwińska A; Rogalska A
    Sci Rep; 2023 Dec; 13(1):22659. PubMed ID: 38114660
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Suberoylanilide hydroxamic acid (SAHA) enhances olaparib activity by targeting homologous recombination DNA repair in ovarian cancer.
    Konstantinopoulos PA; Wilson AJ; Saskowski J; Wass E; Khabele D
    Gynecol Oncol; 2014 Jun; 133(3):599-606. PubMed ID: 24631446
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Bioluminescence detection of cells having stabilized p53 in response to a genotoxic event.
    Rehemtulla A; Taneja N; Ross BD
    Mol Imaging; 2004 Jan; 3(1):63-8. PubMed ID: 15142413
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Hypoxia Potentiates the Radiation-Sensitizing Effect of Olaparib in Human Non-Small Cell Lung Cancer Xenografts by Contextual Synthetic Lethality.
    Jiang Y; Verbiest T; Devery AM; Bokobza SM; Weber AM; Leszczynska KB; Hammond EM; Ryan AJ
    Int J Radiat Oncol Biol Phys; 2016 Jun; 95(2):772-81. PubMed ID: 27020103
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Combined inhibition of Wee1 and PARP1/2 for radiosensitization in pancreatic cancer.
    Karnak D; Engelke CG; Parsels LA; Kausar T; Wei D; Robertson JR; Marsh KB; Davis MA; Zhao L; Maybaum J; Lawrence TS; Morgan MA
    Clin Cancer Res; 2014 Oct; 20(19):5085-96. PubMed ID: 25117293
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Phase II Study of Olaparib (AZD-2281) After Standard Systemic Therapies for Disseminated Colorectal Cancer.
    Leichman L; Groshen S; O'Neil BH; Messersmith W; Berlin J; Chan E; Leichman CG; Cohen SJ; Cohen D; Lenz HJ; Gold P; Boman B; Fielding A; Locker G; Cason RC; Hamilton SR; Hochster HS
    Oncologist; 2016 Feb; 21(2):172-7. PubMed ID: 26786262
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.